UNSPSC 51293403: Nialamide

This classification denotes a monoamine oxidase inhibitor with the molecular formula C16H18N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2Q0RYM725, chemically known as 4-pyridinecarboxylic acid, 2-(3-oxo-3-((phenylmethyl)amino)propyl)hydrazide (9ci) but generally known as nialamide, which bears US NIH Compound Identifier 4472. European Medicines Agency schedules Nialamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09217MIG.

UNSPSC 51293403 Nialamide is a Commodity code nominally identifying a monoamine oxidase inhibitor antidepressant, but recent state and local procurement activity under this code does not reflect purchases of nialamide itself. Instead, the code has been applied to pharmaceutical procurement and supply-chain initiatives covering a broader range of medications and health-system products, including naloxone, generic multi-source pharmaceuticals, and over-the-counter products. State and local issuing bodies using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, has solicited naloxone and drug deactivation systems through competitive bidding (IFB), while the Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has pursued generic pharmaceuticals and OTC products through formal RFP with nationwide reach including Oregon.

Recent activity is concentrated in the South and Upper Midwest. Seminole County's IFB for naloxone and safe drug deactivation systems, posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries and fixed-fee pricing. The Texas HHS Commission's RFI (HHS0017013), posted April 3, 2026, focused on market intelligence for direct-to-manufacturer prescription fulfillment without traditional pharmacy benefit manager intermediaries. MMCAP's RFP (S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract effectiveness July 1, 2026, and a 3 percent administrative fee. The code shows limited recent relevant activity; the mismatch between nialamide as a discrete pharmaceutical product and the broader pharmaceutical-procurement activity tagged under this code suggests miscoding or classifier drift in the source data.